1. Home
  2. PACS vs BLCO Comparison

PACS vs BLCO Comparison

Compare PACS & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PACS Group Inc.

PACS

PACS Group Inc.

SELL

Current Price

$44.53

Market Cap

6.9B

Sector

N/A

ML Signal

SELL

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

SELL

Current Price

$15.83

Market Cap

6.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PACS
BLCO
Founded
2013
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Ophthalmic Goods
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
6.1B
IPO Year
2024
2022

Fundamental Metrics

Financial Performance
Metric
PACS
BLCO
Price
$44.53
$15.83
Analyst Decision
Strong Buy
Buy
Analyst Count
6
15
Target Price
★ $59.00
$19.39
AVG Volume (30 Days)
★ 747.6K
411.0K
Earning Date
11-18-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 221.05
N/A
EPS
★ 0.97
N/A
Revenue
★ $5,288,932,000.00
$5,101,000,000.00
Revenue This Year
$10.63
$7.68
Revenue Next Year
$11.85
$5.95
P/E Ratio
$45.76
★ N/A
Revenue Growth
★ 29.32
6.47
52 Week Low
$10.31
$14.44
52 Week High
$49.49
$18.92

Technical Indicators

Market Signals
Indicator
PACS
BLCO
Relative Strength Index (RSI) 59.25 32.28
Support Level $43.94 $15.68
Resistance Level $45.78 $17.21
Average True Range (ATR) 1.26 0.43
MACD 0.34 -0.11
Stochastic Oscillator 88.89 18.72

Price Performance

Historical Comparison
PACS
BLCO

About PACS PACS Group Inc.

PACS Group Inc is a post-acute healthcare company mainly focused on delivering skilled nursing care through a portfolio of independently operated facilities. The post-acute care ecosystem serves individuals who need additional help recuperating from acute conditions, illnesses, or serious medical procedures after getting discharged from the hospital. It also provides senior care, assisted living, and independent living options in some of the communities. The company has one reportable segment.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: